)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Gritstone bio
Gritstone bio (GRTS.Q) investor relations material
Gritstone bio has been delisted
Gritstone bio Q2 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2024 earnings summary13 Aug, 2024
Executive summary
Reported a net loss of $23.4 million for Q2 2024 and $63.8 million for the six months ended June 30, 2024, compared to net losses of $35.3 million and $69.2 million for the same periods in 2023.
Revenue for Q2 2024 was $0.9 million, primarily from grant agreements, down from $2.0 million in Q2 2023.
Research and development expenses decreased to $20.8 million in Q2 2024 from $31.0 million in Q2 2023, reflecting cost reductions and a workforce reduction.
Preliminary Phase 2 data for GRANITE suggest potential clinical benefit in front-line metastatic MSS-CRC, with mature PFS data expected in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $55.7 million to $61.7 million as of June 30, 2024, expected to fund operations into Q4 2024.
Financial highlights
Q2 2024 total revenue was $0.9 million, down from $2.0 million in Q2 2023; six-month revenue was $2.7 million, down from $4.4 million year-over-year.
Net loss per share was $(0.16) for Q2 2024 and $(0.49) for the six months, compared to $(0.31) and $(0.60) for the same periods in 2023.
Operating expenses for Q2 2024 were $28.5 million, down from $37.7 million in Q2 2023; six-month operating expenses were $70.1 million, down from $74.9 million.
General and administrative expenses rose to $7.7 million for Q2 2024, up $1.0 million year-over-year, mainly from increased personnel and stock-based compensation.
Other income of $4.8 million in Q2 2024 was due to revaluation of common warrants issued in April 2024.
Outlook and guidance
Existing cash and investments are expected to fund operations into Q4 2024; additional capital is required to continue beyond that period.
If unable to raise funds or renegotiate loan terms, the company expects to be in default of its minimum liquidity requirement in Q4 2024.
Management anticipates continued operating losses and negative cash flows for the foreseeable future.
Mature PFS data for GRANITE in MSS-CRC expected in Q3 2024.
Updates on the head-to-head Phase 2b study of the next-generation COVID-19 vaccine (CORAL) to be provided as available.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gritstone bio
Gritstone bio
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Gritstone bio Inc. is a biotechnology company that develops immunotherapies aimed at treating cancer and infectious diseases. The company leverages its expertise in genomics, machine learning, and immune system biology to create therapeutic vaccines and antibody-based treatments. Gritstone bio focuses on advancing precision medicine through innovative platforms designed to stimulate the immune system to recognize and combat specific disease targets. The company is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.